Tandem Diabetes Care (TNDM) Share-based Compensation Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.10% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 5.54% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 5.09% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 14.70% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 5.29% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 7.15% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 13.40% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 12.36% |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | -9.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.59% |
| Dec 31, 2025 | -6.29% |
| Sep 30, 2025 | -1.67% |
| Jun 30, 2025 | 8.40% |
| Mar 31, 2025 | 12.07% |
| Dec 31, 2024 | 18.10% |
| Sep 30, 2024 | 18.66% |
| Jun 30, 2024 | 18.46% |
| Mar 31, 2024 | 19.40% |
| Dec 31, 2023 | 19.55% |
| Sep 30, 2023 | 17.34% |
| Jun 30, 2023 | 12.53% |
| Mar 31, 2023 | 10.13% |
| Dec 31, 2022 | 9.36% |
| Sep 30, 2022 | 8.87% |
| Jun 30, 2022 | 17.78% |
| Mar 31, 2022 | 22.57% |
| Dec 31, 2021 | 18.37% |
| Sep 30, 2021 | 18.15% |
| Jun 30, 2021 | 77.06% |
| Mar 31, 2021 | 121.46% |
| Dec 31, 2020 | 84.30% |
| Sep 30, 2020 | 75.08% |
| Jun 30, 2020 | 89.84% |
| Mar 31, 2020 | 74.93% |
| Dec 31, 2019 | 85.51% |
| Sep 30, 2019 | 81.01% |
| Jun 30, 2019 | 59.63% |
| Mar 31, 2019 | 52.00% |
| Dec 31, 2018 | 49.49% |
| Sep 30, 2018 | 47.42% |
| Jun 30, 2018 | -6.11% |
| Mar 31, 2018 | -31.89% |
| Dec 31, 2017 | -18.64% |
| Sep 30, 2017 | -13.89% |
| Jun 30, 2017 | -12.08% |
| Mar 31, 2017 | -7.71% |
| Dec 31, 2016 | 0.94% |
| Sep 30, 2016 | 44.38% |
| Jun 30, 2016 | 72.71% |
| Mar 31, 2016 | 268.40% |